March
20,
2023
|
07:59 AM
Europe/Amsterdam
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
Not intended for U.S. and UK Media
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial
March
14,
2023
|
12:59 PM
Europe/Amsterdam
Ready-to-use AgPowered Services from Bayer running on the new Microsoft Azure Data Manager for Agriculture / Readymade capabilities and robust digital infrastructure allow innovators to focus on differentiated value / Companies, farmers and …
March
14,
2023
|
12:45 PM
Europe/Amsterdam
Rune Labs’ StriveStudy platform and Emerald Innovations’ Emerald wireless monitoring sensor will passively capture data on Parkinson’s disease impact on function of fifty study participants in BlueRock’s global non-interventional clinical study. / …
March
09,
2023
|
16:14 PM
Europe/Amsterdam
Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that Gustavo Pesquin will become the company’s next Chief Executive Officer …
March
07,
2023
|
08:59 AM
Europe/Amsterdam
Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational …
March
06,
2023
|
09:59 AM
Europe/Amsterdam
New real world study data on reduced risk of adverse kidney outcomes for Xarelto™ compared to VKA
Not intended for U.S. and UK Media - Data presented at American College of Cardiology (ACC.23)
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced …
March
01,
2023
|
11:59 AM
Europe/Amsterdam
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
Not intended for U.S. and UK Media
European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data
March
01,
2023
|
07:59 AM
Europe/Amsterdam
Bayer submits aflibercept 8 mg for marketing authorization in Japan
Not intended for U.S. and UK Media
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, …
February
28,
2023
|
07:30 AM
Europe/Amsterdam
Bayer: Significant growth in sales and earnings
Fiscal 2022
Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases …
February
28,
2023
|
07:29 AM
Europe/Amsterdam
Presskit
February
27,
2023
|
15:29 PM
Europe/Amsterdam
LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapies